E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hereditary Angioedema (HAE) |
|
E.1.1.1 | Medical condition in easily understood language |
HAE is a long-term and life-threatening disease. HAE manifests clinically as unpredictable, intermittent attacks of edema of the face, larynx, gastrointestinal tract, limbs and/or genitalia. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10075280 |
E.1.2 | Term | Hereditary angioedema attack |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10019860 |
E.1.2 | Term | Hereditary angioedema |
E.1.2 | System Organ Class | 10010331 - Congenital, familial and genetic disorders |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of repeated SC administrations of lanadelumab in Japanese subjects with hereditary angioedema (HAE).
|
|
E.2.2 | Secondary objectives of the trial |
To evaluate the efficacy of repeated subcutaneous (SC) administrations of lanadelumab in Japanese subjects with hereditary angioedema (HAE). - To evaluate the safety of repeated SC administrations of lanadelumab in Japanese subjects with HAE. - To evaluate the pharmacokinetics (PK) of repeated SC administrations of lanadelumab in Japanese subjects with HAE. - To evaluate the effect of repeated SC administrations of lanadelumab on health-related quality of life (HRQoL) in Japanese subjects with HAE. - To evaluate the pharmacodynamics (PD) of repeated SC administrations of lanadelumab in Japanese subjects with HAE. - To evaluate the immunogenicity of repeated SC administration of lanadelumab and the effect on lanadelumab PK, PD, efficacy, and safety in Japanese subjects with HAE. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Be of Japanese descent, defined as born in Japan and having Japanese parents and Japanese maternal and paternal grandparents. 2. The subject is male or female and ≥12 years of age at the time of informed consent. 3. Documented diagnosis of HAE (Type I or II) based upon all of the following: a. Documented clinical history consistent with HAE (subcutaneous or mucosal, nonpruritic swelling episodes without accompanying urticaria). b. Diagnostic testing results obtained during screening that confirm HAE Type I or II: C1 inhibitor (C1-INH) functional level less than (<)40 percent (%) of the normal level. Subjects with functional C1-INH level 40-50% of the normal level may be enrolled if they also have a C4 level below the normal range. With prior sponsor approval, subject may be retested during the run-in period if results are in congruent with clinical history or believed by the investigator to be confounded by recent C1 inhibitor use. c. At least one of the following: age at reported onset of first angioedema symptoms ≤30 years, a family history consistent with HAE Type I or II, or C1q within normal range. 4. Attack rate: subjects must experience at least 1 investigator-confirmed HAE attack per 4 weeks during the run-in period to enter the lanadelumab treatment period. 5. The subject (or the subjects parent/legal authorized representative, if applicable) has provided written informed consent approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). 6. If the subject is an adult, be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed or if the subject is a minor (ie, below the age of majority), have a parent/legally authorized representative who is informed of the nature of the study provide written informed consent (ie, permission) for the minor to participate in the study before any study-specific procedures are performed. Assent will be obtained from minor subjects. 7. Males, or non pregnant, non lactating females who are fertile and sexually active and who agree to be abstinent or agree to comply with the applicable contraceptive requirements of this protocol for the duration of the study, or females of non child bearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) or postmenopausal for at least 12 months. 8. Agree to adhere to the protocol-defined schedule of assessments and procedures. |
|
E.4 | Principal exclusion criteria |
1. Concomitant diagnosis of another form of chronic, recurrent angioedema, such as acquired angioedema (AAE), HAE with normal C1-INH (also known as HAE Type 3), idiopathic angioedema, or recurrent angioedema associated with urticaria. 2. Participation in a prior lanadelumab study. 3. Dosing with investigational drug or exposure to an investigational device within 4 weeks prior to entering to screening. 4. Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systematic absorption (such as oral contraceptives or hormonal replacement therapy) within 4 weeks prior to screening. 5. Exposure to androgens (eg, danazol, methyltestosterone, testosterone) within 2 weeks prior to entering the run-in period. 6. Use of long-term prophylactic therapy for HAE (C1-INH, attenuated androgens, or anti-fibrinolytics) within 2 weeks prior to entering the run in period. 7. Use of short-term prophylaxis for HAE 7 days prior to entering the run-in period. Short-term prophylaxis is defined as C1-INH, attenuated androgens, or anti-fibrinolytics used to avoid angioedema complications from medically indicated procedures. 8. Any of the following liver function abnormalities: alanine aminotransferase (ALT) > 3x upper limit of normal, or aspartate aminotransferase (AST) >3x upper limit of normal or bilirubin >2x upper limit of normal (unless the bilirubin is a result of Gilbert's syndrome). 9. Pregnancy or breast feeding. 10. Subject has any condition that in the opinion of the investigator or sponsor, may compromise their safety or compliance, preclude successful conduct of the study, or interfere with interpretation of the results (eg, history of substance abuse, or dependence, significant preexisting illnesses or major comorbidity the investigator considers may confound the interpretation of the study results). 11. Subject has a known hypersensitivity to the IP or its components. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Investigator-Confirmed HAE Attack-Free |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
- Number of Investigator-Confirmed HAE Attacks - Number of Investigator-Confirmed HAE Attacks Requiring Acute Treatment - Number of Investigator-Confirmed Moderate or Severe HAE Attacks - Number of High-Morbidity Investigator-Confirmed HAE Attacks - Number of Investigator-Confirmed HAE Attacks Per Study Month - Time to First Investigator-Confirmed HAE - Subject Level Characteristics of Investigator-Confirmed HAE Attacks (Attack Duration, Attack Severity) - Event Level Characteristics of Investigator-Confirmed HAE Attacks (Attack location, Rescue Medication Use, Supportive Medication Use) - Investigator-Confirmed HAE Attack Rate Reduction Relative to the Run-in Period - Investigator-Confirmed HAE Attacks Rate by Responder Threshold - Investigator-Confirmed HAE Attack-Free per Study Month - Investigator-Confirmed HAE Attack-Free by Interval - Investigator-Confirmed HAE Attack-Free Days - Investigator-Confirmed HAE Attacks by Immunogenicity Results - Plasma Concentration of Lanadelumab - Plasma Kallikrein Activity - Angioedema Quality of Life - Number of Investigator-Confirmed HAE Attacks in Subjects with Dose Modification
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Secondary end points will be assessed throughout the study. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | Yes |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 15 |